Cargando…

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans

Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of antidiabetes drugs, and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus (T2DM). It is widely accepted that SGLT2 is responsible for >80% of the reabsorpt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdul-Ghani, Muhammad A., DeFronzo, Ralph A., Norton, Luke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Perspectives in Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781482/ https://www.ncbi.nlm.nih.gov/pubmed/24065789 http://dx.doi.org/10.2337/db13-0604

Ejemplares similares

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
por: Liu, Jiwen (Jim), et al.
Publicado: (2012)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

A hypothesis explaining why so many pathogen virulence proteins are moonlighting proteins
por: Franco-Serrano, Luis, et al.
Publicado: (2018)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
por: Tuttle, Katherine R., et al.
Publicado: (2021)

β-Cell Growth and Regeneration: Replication Is Only Part of the Story
por: Bonner-Weir, Susan, et al.
Publicado: (2010)

Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects
por: Eldor, Roy, et al.
Publicado: (2017)

FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure
por: Qin, Yuejuan, et al.
Publicado: (2023)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Accurate Measurement of Postprandial Glucose Turnover: Why Is It Difficult and How Can It Be Done (Relatively) Simply?
por: Rizza, Robert A., et al.
Publicado: (2016)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
por: Kanat, Mustafa, et al.
Publicado: (2012)

The Relationship Between β-Cell Function and Glycated Hemoglobin: Results from the Veterans Administration Genetic Epidemiology Study
por: Kanat, Mustafa, et al.
Publicado: (2011)

Why does caloric restriction increase life and healthspan? The ‘clean cupboards’ hypothesis
por: Speakman, John R
Publicado: (2020)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions
por: Nathan, David M., et al.
Publicado: (2013)

Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?
por: Jatoi, Ismail, et al.
Publicado: (2018)

Celebrating 30 Years of Research Accomplishments of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
por: Fradkin, Judith E., et al.
Publicado: (2013)

Do superspreaders generate new superspreaders? A hypothesis to explain the propagation pattern of COVID-19
por: Beldomenico, Pablo M.
Publicado: (2020)

Revisiting the ‘direct mineral cycling’ hypothesis: arbuscular mycorrhizal fungi colonize leaf litter, but why?
por: Bunn, Rebecca A., et al.
Publicado: (2019)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2008)

Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance
por: Shannon, Chris, et al.
Publicado: (2018)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells
por: Norton, Luke, et al.
Publicado: (2014)

Pregnancies in Diabetes and Obesity: The Capacity-Load Model of Placental Adaptation
por: Desoye, Gernot, et al.
Publicado: (2021)

Support for mechanical advantage hypothesis of grasping cannot be explained only by task mechanics
por: Rajakumar, Banuvathy, et al.
Publicado: (2022)

Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
por: Daniele, Giuseppe, et al.
Publicado: (2020)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

SUN-181 Case Report: Rare Complication of SGLT2 Inhibitors Can Occur Only 10 Days after Starting the Medication
por: Elshimy, Ghada, et al.
Publicado: (2019)

Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Self-measurement of Blood Glucose and Continuous Glucose Monitoring – Is There Only One Future?
por: Heinemann, Lutz, et al.
Publicado: (2018)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cqo3p7oi75lmkisgd5qee846j9